<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03377036</url>
  </required_header>
  <id_info>
    <org_study_id>UKM14_0016</org_study_id>
    <secondary_id>HE1646/5-1</secondary_id>
    <nct_id>NCT03377036</nct_id>
  </id_info>
  <brief_title>Breast Cancer Screening: Digital Breast Tomosynthesis Versus Digital 2D Mammography</brief_title>
  <acronym>TOSYMA</acronym>
  <official_title>Prospective Randomized Comparison of Digital Breast Tomosynthesis Plus Synthesized Images Versus Standard Full-field Digital Mammography in Population-based Screening (TOSYMA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Muenster</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Muenster</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, multicenter, multivendor, controlled, diagnostic superiority
      trial to compare digital breast tomosynthesis plus synthesized 2D mammograms (DBT+s2D) versus
      standard 2D full-field digital mammography (2D-FFDM) regarding the effectiveness as screening
      modality.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the study is to evaluate whether digital breast tomosynthesis plus
      synthesized 2D mammograms leads to a relevant increase in the detection rate of
      screening-detected invasive cancers compared to 2D full-field digital mammography in routine
      screening according to the European Guidelines. Furthermore, the incidence rate of interval
      cancers within a 24 months interval after screening will be compared between both study arms
      in order to investigate the potential for overdiagnosis.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2018</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomized to either Digital Breast Tomosynthesis plus synthesized 2D mammograms (DBT+s2D) or 2D Full-Field Digital Mammography (2D-FFDM)</intervention_model_description>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Detection rate of invasive breast cancers</measure>
    <time_frame>Routine screening visit</time_frame>
    <description>Number of women with screening-detected invasive breast cancer divided by the number of all women screened. A screening-detected breast cancer is classified as invasive carcinoma if the pT category (pathological tumor size) of the TNM classification falls into one of the following categories: pT1mic, pT1a, pT1b, pT1c, pT1, pT2, pT3, pT4a, pT4b, pT4c, pT4d, pT4, pTX (for evaluation purpose pTX defines histologically approved invasive breast cancer with missing tumor diameter) or the final pathological categorization has been done after neoadjuvant therapy (ypT), implying an invasive cancer prior to therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative 24 months incidence of interval cancers</measure>
    <time_frame>24 months after routine screening visit</time_frame>
    <description>The 24 months incidence of interval cancers is defined as the number of women that develop a ductal carcinoma in situ or an invasive breast cancer in the 24 months interval after a negative screening examination divided by the number of all women with a negative screening result.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detection rate of ductal carcinoma in situ (DCIS)</measure>
    <time_frame>Routine screening visit</time_frame>
    <description>Number of women with screening-detected ductal carcinoma in situ (if the pT category of the TNM classification falls into the category pTis) divided by the number of all women screened.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection rate of tumor category pT1</measure>
    <time_frame>Routine screening visit</time_frame>
    <description>Number of women with screening-detected invasive breast cancers of the category pT1 divided by the number of all women screened. A screening-detected breast cancer is classified as breast cancer of tumor category pT1 if tumor size is ≤ 20 mm in greatest dimension and the respective pT subcategory of the pTNM classification is one of the following: pT1mic, pT1a, pT1b, pT1c, pT1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recall rate for further assessment</measure>
    <time_frame>Routine Screening Visit</time_frame>
    <description>Number of women with recalls for further assessment divided by the number of all women screened.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive predictive value of recall for further assessment (PPV1)</measure>
    <time_frame>Routine screening visit</time_frame>
    <description>Number of women with screening-detected malignancies (ductal carcinoma in situ or invasive breast cancer) divided by the number of women with recalls for further assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative 12 months incidence of interval cancers</measure>
    <time_frame>12 months after routine screening visit</time_frame>
    <description>The 12 months incidence of interval cancers is defined as the number of women that develop a ductal carcinoma in situ or an invasive breast cancer in the 12 months interval after a negative screening examination divided by the number of all women with a negative screening result.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80000</enrollment>
  <condition>Breast Cancer Screening</condition>
  <arm_group>
    <arm_group_label>DBT+s2D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Digital breast tomosynthesis plus synthesized 2D mammograms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2D-FFDM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2D full-field digital mammography</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>DBT+s2D</intervention_name>
    <description>Digital breast tomosynthesis plus synthesized 2D mammograms</description>
    <arm_group_label>DBT+s2D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>2D-FFDM</intervention_name>
    <description>2D full-field digital mammography</description>
    <arm_group_label>2D-FFDM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women eligible to participate in the National Mammography Screening Program of Germany

          -  Informed decision for mammography screening

          -  Written informed consent

        Exclusion Criteria:

          -  Breast cancer up to 5 years prior to study invitation

          -  Previous mammography examination &lt; 12 months,

          -  Breast implants
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter Heindel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Clinical Radiology University of Münster / University Hospital Münster</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Walter Heindel, MD, PhD</last_name>
    <phone>+49 251 83</phone>
    <phone_ext>45650</phone_ext>
    <email>heindel@uni-muenster.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stefanie Weigel, MD, PhD</last_name>
    <email>weigels@uni-muenster.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Screening-Einheit Hannover; Mammographie-Einheit Hannover</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30449</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Verantwortlicher Studienarzt: Regine Rathmann</last_name>
    </contact>
    <contact_backup>
      <last_name>Verantwortlicher Studienarzt: Dr. med. Guido Süttmann</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Screening-Einheit Niedersachsen Nordost; Mammographie-Einheit Lüneburg</name>
      <address>
        <city>Lüneburg</city>
        <state>Niedersachsen</state>
        <zip>21337</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Verantwortlicher Studienarzt: Dr. med. Karl Struckmann</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Screening-Einheit Niedersachsen Nord; Mammographie-Einheit Stade</name>
      <address>
        <city>Stade</city>
        <state>Niedersachsen</state>
        <zip>21680</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Verantwortlicher Studienarzt: Dr. med. Thilo Töllner</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Screening-Einheit Niedersachsen Mitte; Mammographie-Einheit Vechta</name>
      <address>
        <city>Vechta</city>
        <state>Niedersachsen</state>
        <zip>49377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Verantwortlicher Studienarzt: Dr. med. Jens Bruns</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Screening-Einheit Niedersachsen Nordwest; Mammographie-Einheit Wilhelmshaven</name>
      <address>
        <city>Wilhelmshaven</city>
        <state>Niedersachsen</state>
        <zip>26382</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Verantwortlicher Studienarzt: Dr. med. Gerold Hecht</last_name>
    </contact>
    <contact_backup>
      <last_name>Verantwortlicher Studienarzt: Dr. med. Margret Ganseforth</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Screening-Einheit Aachen-Düren-Heinsberg; Mammographie-Einheit Aachen</name>
      <address>
        <city>Aachen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>52062</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Referenz-Screening-Einheit Münster-Nord/Warendorf; Mammographie-Einheit Ahlen</name>
      <address>
        <city>Ahlen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>59227</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Verantwortlicher Studinarzt: Prof. Dr. med. Walter Heindel</last_name>
    </contact>
    <contact_backup>
      <last_name>Verantwortlicher Studienarzt: PD Dr. med. Stefanie Weigel</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Screening-Einheit Köln rechtsrheinisch, Leverkusen, Rhein.-Berg. Kreis, Oberbergischer Kreis; Mammographie-Einheit Bergisch Gladbach</name>
      <address>
        <city>Bergisch Gladbach</city>
        <state>Nordrhein-Westfalen</state>
        <zip>51429</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Verantwortliche Studienärztin: Dr. med. Caroline Dietz</last_name>
    </contact>
    <contact_backup>
      <last_name>Verantwortliche Studienärztin: Christina Barduna</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Screening-Einheit Bielefeld, Gütersloh; Mammographie-Einheit Bielefeld</name>
      <address>
        <city>Bielefeld</city>
        <state>Nordrhein-Westfalen</state>
        <zip>33062</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Verantwortlicher Studienarzt: Dr. med. Ulrike Meyer-Johann</last_name>
    </contact>
    <contact_backup>
      <last_name>Verantwortlicher Studienarzt: Joachim Ritter</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Screening-Einheit Münster-Süd; Mammographie-Einheit Coesfeld</name>
      <address>
        <city>Coesfeld</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48653</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Verantwortlicher Studienarzt: Simona-Carmen Spital</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Screening-Einheit Duisburg; Mammographie-Einheit Duisburg</name>
      <address>
        <city>Duisburg</city>
        <state>Nordrhein-Westfalen</state>
        <zip>47057</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Verantwortlicher Studienarzt: Dr. med. Michael Hirning</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Screening-Einheit Gelsenkirchen, Kreis Recklinghausen, Bottrop; Mammographie-Einheit Gelsenkirchen</name>
      <address>
        <city>Gelsenkirchen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45894</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Verantwortlicher Studienarzt: Dr. med. Thomas Lehnen</last_name>
    </contact>
    <contact_backup>
      <last_name>Verantwortlicher Studienarzt: Dr. med. Doris Polenske</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Screening-Einheit Minden-Lübbecke, Herford; Mammographie-Einheit Herford</name>
      <address>
        <city>Herford</city>
        <state>Nordrhein-Westfalen</state>
        <zip>32052</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Verantwortlicher Studienarzt: Dr. med. Gisela Urban</last_name>
    </contact>
    <contact_backup>
      <last_name>Verantwortlicher Studienarzt: Dr. med. Annette Rudolf</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Screening-Einheit Mönchengladbach, Krefeld, Viersen; Mammographie-Einheit Krefeld</name>
      <address>
        <city>Krefeld</city>
        <state>Nordrhein-Westfalen</state>
        <zip>47805</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Verantwortlicher Studienarzt: Ingo Wendt</last_name>
    </contact>
    <contact_backup>
      <last_name>Verantwortlicher Studienarzt: Dr. med. Peter Liersch</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Screening-Einheit Höxter, Paderborn, Soest; Mammographie-Einheit Lippstadt</name>
      <address>
        <city>Lippstadt</city>
        <state>Nordrhein-Westfalen</state>
        <zip>59555</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Verantwortlicher Studienarzt: Jost Porrmann</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Referenz-Screeening-Einheit Münster-Nord/Warendorf; Mammographie-Einheit Münster-Nord</name>
      <address>
        <city>Münster</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48143</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Verantwortlicher Studienarzt: Prof. Dr. med. Walter Heindel</last_name>
    </contact>
    <contact_backup>
      <last_name>Verantwortlicher Studienarzt: PD Dr. med. Stefanie Weigel</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Screening-Einheit Münster-Süd; Mammographie-Einheit Münster</name>
      <address>
        <city>Münster</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48153</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Verantwortlicher Studienarzt: Simona-Carmen Spital</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Screening-Einheit Höxter, Paderborn, Soest; Mammographie-Einheit Paderborn</name>
      <address>
        <city>Paderborn</city>
        <state>Nordrhein-Westfalen</state>
        <zip>33098</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Verantwortlicher Studienarzt: Dr. med. Axel Gräwingholt</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Screening-Einheit Märkischer Kreis, Hamm, Unna; Mammographie-Einheit Schwerte</name>
      <address>
        <city>Schwerte</city>
        <state>Nordrhein-Westfalen</state>
        <zip>58239</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Verantwortlicher Studienarzt: Dr. Ulrich Krause</last_name>
    </contact>
    <contact_backup>
      <last_name>Verantwortlicher Studienarzt: Bele Dablé</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Screening-Einheit Raum Bergisch Land/Kreis Mettmann; Mammographie-Einheit Solingen-Mitte</name>
      <address>
        <city>Solingen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>42651</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Verantwortlicher Studienarzt: Dr. med. Markus Stuhrmann</last_name>
    </contact>
    <contact_backup>
      <last_name>Verantwortlicher Studienarzt: Dr. med. Kirsten Schulze</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Screening-Einheit Raum Bergisch Land/Kreis Mettmann; Mammographie-Einheit Wuppertal-Elberfeld</name>
      <address>
        <city>Wuppertal</city>
        <state>Nordrhein-Westfalen</state>
        <zip>42109</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Verantwortlicher Studienarzt: Dr. med. Markus Stuhrmann</last_name>
    </contact>
    <contact_backup>
      <last_name>Verantwortlicher Studienarzt: Dr. med. Kirsten Schulze</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://bmjopen.bmj.com/content/8/5/e020475</url>
    <description>BMJ Open</description>
  </link>
  <reference>
    <citation>Weigel S, Gerss J, Hense H, et al. Digital breast tomosynthesis plus synthesised images versus standard full-field digital mammography in population-based screening (TOSYMA): protocol of a randomised controlled trial. BMJ Open 2018;8:e020475. doi: 10.1136/bmjopen-2017-020475</citation>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2017</study_first_submitted>
  <study_first_submitted_qc>December 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2017</study_first_posted>
  <last_update_submitted>May 22, 2018</last_update_submitted>
  <last_update_submitted_qc>May 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Population-based Screening</keyword>
  <keyword>Digital Breast Tomosynthesis plus synthesized Mammography</keyword>
  <keyword>Reconstructed Mammography</keyword>
  <keyword>Full-Field Digital Mammography (FFDM)</keyword>
  <keyword>Multicentric Randomized Controlled Trial</keyword>
  <keyword>Diagnostic Performance</keyword>
  <keyword>Recall Rate</keyword>
  <keyword>Interval Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

